Assembly Biosciences, Inc. reported $37M of revenue over the trailing twelve months. 8 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $37M (to Q3 2025). Net income: −$42K, trailing twelve months to Q2 2026. Free cash flow: −$39M, trailing twelve months to Q2 2026. Operating margin: −120%, trailing twelve months to Q3 2025.

ASMBAssembly Biosciences, Inc.

Healthcare

$22.80-4.4% 1Y

$22.80

$22.1952 weeks$38.50

ASMB as reported

Assembly Biosciences, Inc. reported $37M of revenue over the trailing twelve months. 8 reported series are charted on this page, each one as filed.

$37M

Revenue, trailing twelve months · to Q3 2025 · every figure below is as filed, with no scoring applied

Net income: −$42K
Net income · −100% year on year · trailing twelve months to Q2 2026
Free cash flow: −$39M
Free cash flow · −31% year on year · trailing twelve months to Q2 2026
Operating margin: −120%
Operating margin · trailing twelve months to Q3 2025

Details›

Every series Ryufin has for ASMB, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$37M	n/a	Q3 2025
Net income	−$42K	−100%	Q2 2026
EPS	$1.02	−118%	Q2 2026
Operating margin	−120%	n/a	Q3 2025
Net margin	−106%	n/a	Q3 2025
ROE	−6.8%	n/a	Q2 2026
ROA	−5.3%	n/a	Q2 2026
Free cash flow	−$39M	−31%	Q2 2026

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.